Role of Plasminogen Activator Inhibitor-1 in Senescence and Aging

Abstract

The average age of the US population continues to increase. Age is the most important determinant of disease and disability in humans, but the fundamental mechanisms of aging remain largely unknown. Many age-related diseases are associated with an impaired fibrinolytic system. Elevated plasminogen activator inhibitor-1 (PAI-1) levels are reported in age-associated clinical conditions including cardiovascular diseases, type 2 diabetes, obesity and inflammation. PAI-1 levels are also elevated in animal models of aging. While the association of PAI-1 with physiological aging is well documented, it is only recently that its critical role in the regulation of aging and senescence has become evident. PAI-1 is synthesized and secreted in senescent cells and contributes directly to the development of senescence by acting downstream of p53 and upstream of insulin-like growth factor binding protein-3. Pharmacologic inhibition or genetic deficiency of PAI-1 was shown to be protective against senescence and the aging-like phenotypes in kl/kl and N^ω-nitro-l-arginine methyl ester–treated wild-type mice. Further investigation into PAI-1's role in senescence and aging will likely contribute to the prevention and treatment of aging-related pathologies.

Keywords

PAI-1 - senescence - aging

• References

• 1 Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011; 192 (4) 547-556
• 2 Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8 (9) 729-740
• 3 Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86 (1) 324-333
• 4 Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18 (7) 1035-1045
• 5 Abbate R, Prisco D, Rostagno C, Boddi M, Gensini GF. Age-related changes in the hemostatic system. Int J Clin Lab Res 1993; 23 (1) 1-3
• 6 Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 1995; 46 (8) 715-718
• 7 Meade TW, Chakrabarti R, Haines AP, North WR, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ 1979; 1 (6157) 153-156
• 8 Aillaud MF, Pignol F, Alessi MC , et al. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost 1986; 55 (3) 330-332
• 9 Aznar J, Estellés A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis 1994; 24 (4) 243-251
• 10 Smith LH, Dixon JD, Stringham JR , et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107 (1) 132-134
• 11 Meltzer ME, Lisman T, de Groot PG , et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116 (1) 113-121
• 12 Thögersen AM, Jansson JH, Boman K , et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98 (21) 2241-2247
• 13 Hamsten A, de Faire U, Walldius G , et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2 (8549) 3-9
• 14 Kochtebane N, Alzahrani AM, Bartegi A. Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. Biochem Res Int 2014; 2014: 658643
• 15 Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78 (1) 656-660
• 16 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26 (10) 2200-2207
• 17 Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 1989; 264 (18) 10396-10401
• 18 Estellés A, Dalmau J, Falcó C , et al. Plasma PAI-1 levels in obese children—effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001; 86 (2) 647-652
• 19 Lindeman JH, Pijl H, Toet K , et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes (Lond) 2007; 31 (11) 1671-1679
• 20 Barbato A, Iacone R, Tarantino G , et al; Olivetti Heart Study Research Group. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern Emerg Med 2009; 4 (4) 315-323
• 21 Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51 (4) 1131-1137
• 22 Kanaya AM, Wassel Fyr C, Vittinghoff E , et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006; 166 (3) 350-356
• 23 Schneiderman J, Sawdey MS, Keeton MR , et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89 (15) 6998-7002
• 24 Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15 (9) 1432-1443
• 25 Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15 (9) 1444-1455
• 26 Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16 (4) 539-545
• 27 Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97 (22) 2213-2221
• 28 Pandolfi A, Cetrullo D, Polishuck R , et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001; 21 (8) 1378-1382
• 29 Hou B, Eren M, Painter CA , et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 2004; 279 (18) 18127-18136
• 30 Quax PH, van den Hoogen CM, Verheijen JH , et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265 (26) 15560-15563
• 31 Arndt PG, Young SK, Worthen GS. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway. J Immunol 2005; 175 (6) 4049-4059
• 32 Yamamoto K, Shimokawa T, Yi H , et al. Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol 2002; 161 (5) 1805-1814
• 33 Sobel BE, Lee YH, Pratley RE, Schneider DJ. Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. Life Sci 2006; 79 (17) 1600-1605
• 34 Balaoing LR, Post AD, Liu H, Minn KT, Grande-Allen KJ. Age-related changes in aortic valve hemostatic protein regulation. Arterioscler Thromb Vasc Biol 2014; 34 (1) 72-80
• 35 Yamamoto K, Takeshita K, Shimokawa T , et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A 2002; 99 (2) 890-895
• 36 Emeis JJ, Van den Hoogen CM. Pharmacological modulation of the endotoxin-induced increase in plasminogen activator inhibitor activity in rats. Blood Coagul Fibrinolysis 1992; 3 (5) 575-581
• 37 Kuro-o M, Matsumura Y, Aizawa H , et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390 (6655) 45-51
• 38 Takeshita K, Yamamoto K, Ito M , et al. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, “Klotho” mouse. Semin Thromb Hemost 2002; 28 (6) 545-554
• 39 Baker DJ, Perez-Terzic C, Jin F , et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol 2008; 10 (7) 825-836
• 40 Baker DJ, Wijshake T, Tchkonia T , et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011; 479 (7372) 232-236
• 41 Burt VL, Cutler JA, Higgins M , et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26 (1) 60-69
• 42 Boe AE, Eren M, Murphy SB , et al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation 2013; 128 (21) 2318-2324
• 43 Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104 (7) 839-844
• 44 Kaikita K, Schoenhard JA, Painter CA , et al. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J Mol Cell Cardiol 2002; 34 (6) 617-627
• 45 Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost 2007; 5 (7) 1500-1508
• 46 Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106 (4) 491-496
• 47 Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120 (4) 513-522
• 48 Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105 (13) 1541-1544
• 49 Chen JH, Hales CN, Ozanne SE. DNA damage, cellular senescence and organismal ageing: causal or correlative?. Nucleic Acids Res 2007; 35 (22) 7417-7428
• 50 Cardus A, Uryga AK, Walters G, Erusalimsky JD. SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence. Cardiovasc Res 2013; 97 (3) 571-579
• 51 Comi P, Chiaramonte R, Maier JA. Senescence-dependent regulation of type 1 plasminogen activator inhibitor in human vascular endothelial cells. Exp Cell Res 1995; 219 (1) 304-308
• 52 Martens JW, Sieuwerts AM, Bolt-deVries J , et al. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb Haemost 2003; 89 (2) 393-404
• 53 Mu XC, Higgins PJ. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J Cell Physiol 1995; 165 (3) 647-657
• 54 Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88 (5) 593-602
• 55 West MD, Shay JW, Wright WE, Linskens MH. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp Gerontol 1996; 31 (1-2) 175-193
• 56 Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006; 6 (6) 472-476
• 57 Goldstein S, Moerman EJ, Fujii S, Sobel BE. Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J Cell Physiol 1994; 161 (3) 571-579
• 58 Kortlever RM, Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 2006; 5 (23) 2697-2703
• 59 Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8 (8) 877-884
• 60 Elzi DJ, Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y. Plasminogen activator inhibitor 1—insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc Natl Acad Sci U S A 2012; 109 (30) 12052-12057
• 61 Kortlever RM, Brummelkamp TR, van Meeteren LA, Moolenaar WH, Bernards R. Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res 2008; 6 (9) 1452-1460
• 62 Lara PC, Lloret M, Valenciano A , et al. Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors. Strahlenther Onkol 2012; 188 (12) 1139-1145
• 63 Offersen BV, Alsner J, Ege Olsen K , et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008; 47 (4) 618-632
• 64 Testa R, Bonfigli AR, Salvioli S , et al. The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing. Mech Ageing Dev 2009; 130 (8) 497-500
• 65 Eren M, Boe AE, Murphy SB , et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci U S A 2014; 111 (19) 7090-7095
• 66 Nelson G, Wordsworth J, Wang C , et al. A senescent cell bystander effect: senescence-induced senescence. Aging Cell 2012; 11 (2) 345-349
• 67 Heberlein KR, Han J, Straub AC , et al. A novel mRNA binding protein complex promotes localized plasminogen activator inhibitor-1 accumulation at the myoendothelial junction. Arterioscler Thromb Vasc Biol 2012; 32 (5) 1271-1279
• 68 Heberlein KR, Straub AC, Best AK , et al. Plasminogen activator inhibitor-1 regulates myoendothelial junction formation. Circ Res 2010; 106 (6) 1092-1102